Screener
Organon OGN NuvaRing — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| Women’s Health | ||||||
| Nexplanon/Implanon NXT | $127 | $74 | $201 | $176 | $72 | $248 |
| Follistim AQ | 21 | 39 | 61 | 35 | 34 | 69 |
| NuvaRing | 6 | 18 | 24 | 6 | 16 | 22 |
| Ganirelix Acetate Injection | 2 | 24 | 26 | 5 | 23 | 27 |
| Marvelon/Mercilon | — | 26 | 26 | — | 39 | 39 |
| Jada | 5 | — | 5 | 15 | — | 15 |
| Other Women’s Health (1) | 17 | 30 | 46 | 15 | 27 | 43 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's nuvaring — revenue?
- Organon (OGN) reported nuvaring — revenue of $24M in Q1 2026.
- How has Organon's nuvaring — revenue changed year-over-year?
- Organon's nuvaring — revenue increased by 9.1% year-over-year, from $22M to $24M.
- What is the long-term trend for Organon's nuvaring — revenue?
- Over 4 years (2021 to 2025), Organon's nuvaring — revenue has grown at a -16.7% compound annual growth rate (CAGR), from $191M to $92M.
- What does nuvaring — revenue mean?
- This metric represents the total gross sales generated from the NuvaRing contraceptive product line within the women's health portfolio. It serves as a key indicator of market demand and product lifecycle performance for this specific hormonal therapy. Tracking these revenues helps investors assess the competitive positioning and revenue contribution of established women's health assets against newer market entrants.
Ask your AI about Organon's nuvaring — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude